Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 1997

View Archived Issues

PDL licenses antibody humanization patents to IDEC

Genzyme's second-generation LDL and HDL tests launched in U.S.

Results with PLC Systems' TMR System reported

MGH and BioTransplant report advances in xenotransplantation research

Roche prepares for integration of Boehringer Mannheim and DePuy

Final preclinical results for MRSA test reported

Glaxo Wellcome develops new influenza sialidase inhibitors

Potent and selective COX-2 inhibitors synthesized at Boehringer Ingelheim

New compounds for influenza targeting cap-dependent endonuclease

Merck Frosst reports further data on COX-2 inhibitor L-768277

NCI evaluates stability of SarCNU

Annual Report: Takeda

More on SE-205, a new MMP/TNF inhibitor from DuPont Merck

Potential antipsychotics under development at Taisho/Nihon Nohyaku

Advanced Magnetics' liver contrast agent launched in Japan

Sanofi product pipeline in review

CIMA licenses OraSolv to Zeneca

Eisai discovers potent, optically active triazole antifungal

Apotex launches generic ranitidine in U.S.

Fenfluramine, dexfenfluramine voluntarily withdrawn

Promising preliminary phase III results reported for Lyme disease vaccine

Block Drug to market Atridox in Canada

Preliminary results from phase II/III Sensamide study

Long-term effects of abciximab in PTCA

Natrecor in CHF: phase III results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...